NEW YORK (GenomeWeb News) – Sequenom and CombiMatrix today announced an agreement to market chromosomal microarray analysis testing services "to broaden and confirm the results of non-invasive prenatal testing" to doctors and patients.

Under the terms of the deal, the Sequenom Center for Molecular Medicine and CombiMatrix will promote the use of NIPD testing and CMA, as well as provide technical training to physicians. They also will provide counseling, educational, and support services to physicians and their patients, they said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.